We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Court Blasts FDA, Overturns Pravachol Exclusivity Ruling
An FDA decision that wiped out Teva Pharmaceutical’s market exclusivity for a generic version of Bristol-Myers Squibb’s (BMS) lucrative cholesterol-lowering drug Pravachol (pravastatin sodium) was arbitrary and in violation of federal law, according to a district court judge, who recently granted injunctive relief to Teva.